Bionime Statistics
Total Valuation
Bionime has a market cap or net worth of TWD 4.49 billion. The enterprise value is 6.93 billion.
Important Dates
The next estimated earnings date is Friday, March 12, 2027.
| Earnings Date | Mar 12, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
Bionime has 77.33 million shares outstanding. The number of shares has increased by 10.08% in one year.
| Current Share Class | 77.33M |
| Shares Outstanding | 77.33M |
| Shares Change (YoY) | +10.08% |
| Shares Change (QoQ) | -0.12% |
| Owned by Insiders (%) | 11.18% |
| Owned by Institutions (%) | 0.66% |
| Float | 45.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.59 |
| PB Ratio | 2.25 |
| P/TBV Ratio | 4.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.69, with a Debt / Equity ratio of 1.38.
| Current Ratio | 0.69 |
| Quick Ratio | 0.42 |
| Debt / Equity | 1.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.34 |
Financial Efficiency
Return on equity (ROE) is -15.43% and return on invested capital (ROIC) is -7.47%.
| Return on Equity (ROE) | -15.43% |
| Return on Assets (ROA) | -3.70% |
| Return on Invested Capital (ROIC) | -7.47% |
| Return on Capital Employed (ROCE) | -9.91% |
| Weighted Average Cost of Capital (WACC) | 2.54% |
| Revenue Per Employee | 3.47M |
| Profits Per Employee | -602,936 |
| Employee Count | 500 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 2.47 |
Taxes
| Income Tax | -80.04M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.92% in the last 52 weeks. The beta is -0.22, so Bionime's price volatility has been lower than the market average.
| Beta (5Y) | -0.22 |
| 52-Week Price Change | -4.92% |
| 50-Day Moving Average | 57.50 |
| 200-Day Moving Average | 58.20 |
| Relative Strength Index (RSI) | 51.29 |
| Average Volume (20 Days) | 115,925 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bionime had revenue of TWD 1.73 billion and -301.47 million in losses. Loss per share was -4.08.
| Revenue | 1.73B |
| Gross Profit | 598.95M |
| Operating Income | -329.78M |
| Pretax Income | -378.26M |
| Net Income | -301.47M |
| EBITDA | -179.41M |
| EBIT | -329.78M |
| Loss Per Share | -4.08 |
Full Income Statement Balance Sheet
The company has 334.03 million in cash and 2.77 billion in debt, with a net cash position of -2.44 billion or -31.49 per share.
| Cash & Cash Equivalents | 334.03M |
| Total Debt | 2.77B |
| Net Cash | -2.44B |
| Net Cash Per Share | -31.49 |
| Equity (Book Value) | 2.01B |
| Book Value Per Share | 25.87 |
| Working Capital | -696.86M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -64.16 million and capital expenditures -79.08 million, giving a free cash flow of -143.24 million.
| Operating Cash Flow | -64.16M |
| Capital Expenditures | -79.08M |
| Depreciation & Amortization | 150.37M |
| Net Borrowing | -320.64M |
| Free Cash Flow | -143.24M |
| FCF Per Share | -1.85 |
Full Cash Flow Statement Margins
Gross margin is 34.53%, with operating and profit margins of -19.01% and -17.38%.
| Gross Margin | 34.53% |
| Operating Margin | -19.01% |
| Pretax Margin | -21.81% |
| Profit Margin | -17.38% |
| EBITDA Margin | -10.34% |
| EBIT Margin | -19.01% |
| FCF Margin | n/a |
Dividends & Yields
Bionime does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.08% |
| Shareholder Yield | -10.08% |
| Earnings Yield | -7.03% |
| FCF Yield | -3.19% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on September 8, 2025. It was a forward split with a ratio of 1.0998680158.
| Last Split Date | Sep 8, 2025 |
| Split Type | Forward |
| Split Ratio | 1.0998680158 |
Scores
Bionime has an Altman Z-Score of 0.62 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.62 |
| Piotroski F-Score | 3 |